Laurent Schio

This inventor holds 27 USPTO granted patents and 7 published patent applications, plus 2 CIPO patents and 12 EPO patents, primarily in Pharmaceutical Chemistry. Top assignees: Sanofi, Aventis Pharma S.a., Ucbbiopharma Srl. Active years: 1999-2024.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Laurent Schio. Retrieved from https://idiyas.com/inventor/laurent-schio

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

USPTO Granted Patents = 27 (Patent Applications = 7)

% Patents Active = 44.4

CIPO Patents = 2 (Patent Applications = 2)

EPO Patents = 12 (Patent Applications = 13)

Average Co-Inventor Count = 6.5

ph-index = 5

Forward Citations = 64(Granted Patents)

Location History:

Noisy le Sec, FR (1999)
Bondy, FR (2002 - 2007)
Marolles en Brie, FR (2012 - 2015)
Antony, FR (2015)
Paris, FR (2013 - 2024)

Company Filing History:

Hoechst Marion Roussel

patents

5. 1 out of 8

Lead Pharma Holding B.v.

where one patent can have more than one assignee

Years Active: 1999-2024

Loading Chart...

Areas of Expertise:

Echinocandin Derivatives

Anti-Cancer Compounds

Imidazole Derivatives

Pyrazolylbenzimidazole

Pharmaceutical Composition

Heterocycles

Fluoropropyl-Pyrrolidine

Benzo[7]annulene Compounds

AKT Inhibitors

Aromatic Derivatives

Fungicidal Agents

Therapeutic Uses

27 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 11912721 - Fused pentacyclic imidazole derivatives (2024-02-27),

2. 11214541 - Substituted 6,7-dihydro-5H-benzo[7]annulene compounds, processes for their preparation and therapeutic uses thereof (2022-01-04),

3. 11149031 - Substituted N-(3-fluoropropyl)-pyrrolidine compounds, processes for their preparation and therapeutic uses thereof (2021-10-19),

4. 10906919 - Fused pentacyclic imidazole derivatives (2021-02-02),

5. 10570090 - Substituted 6,7-dihydro-5H-benzo[7]annulene compounds, processes for their preparation and therapeutic uses thereof (2020-02-25),

6. 10202405 - Fused pentacyclic imidazole derivatives (2019-02-12),

7. 10118895 - ROR gamma (RORγ) modulators (2018-11-06),

8. 9714221 - Substituted 6,7-dihydro-5H-benzo[7]annulene compounds, processes for their preparation and therapeutic uses thereof (2017-07-25),

9. 9221817 - Anti-cancer compound and pharmaceutical composition containing the same (2015-12-29),

10. 9126969 - Pyrazolylbenzimidazole derivatives, compositions containing them and use thereof (2015-09-08),

11. 9073917 - Anti-cancer compound and pharmaceutical composition containing the same (2015-07-07),

12. 8993565 - (6-oxo-1,6-dihydropyrimidin-2-yl)amide derivatives, preparation thereof and pharmaceutical use thereof as AKT(PKB) phosphorylation inhibitors (2015-03-31),

13. 8846670 - 1,2,3,4-tetrahydro-pyrimido(1,2-a)pyrimidin-6-one derivatives, preparation thereof, and pharmaceutical use thereof (2014-09-30),

14. 8828997 - 2,3-dihydro-1H-imidazo(1,2-a)pyrimidin-5-one derivatives, preparation thereof, and pharmaceutical use thereof (2014-09-09),

15. 8791255 - (6-oxo-1,6-dihydropyrimidin-2-yl)amide derivatives, preparation thereof and pharmaceutical use thereof as AKT(PKB) phosphorylation inhibitors (2014-07-29),

Title: Innovations and Contributions of Laurent Schio in the Pharmaceutical Sector

Introduction

Laurent Schio, based in Paris, France, is a notable inventor with a significant portfolio of 27 patents. His work focuses on developing therapeutic compounds with the potential to address a wide range of human ailments. Through his innovative research, Schio has made valuable contributions to the pharmaceutical field, particularly in the area of inflammation and disease modulation.

Latest Patents

One of Schio's latest patents includes a series of fused pentacyclic imidazole derivatives. These compounds serve as potent modulators of human TNFα activity and are anticipated to benefit the treatment or prevention of various human ailments. These ailments encompass autoimmune and inflammatory disorders, neurological and neurodegenerative disorders, pain and nociceptive disorders, cardiovascular disorders, metabolic disorders, ocular disorders, and oncological disorders. The patent particularly highlights derivatives of 6, 7-dihydro-7, 14-methanobenzimidazo[1, 2-b][2,5]benzodiazocin-5(14H)-one.

Another significant patent involves substituted 6,7-dihydro-5H-benzo[7]annulene compounds, detailing their preparation processes and therapeutic applications.

Career Highlights

Throughout his career, Laurent Schio has contributed to major pharmaceutical firms, including Sanofi and Aventis Pharma S.A. His expertise in drug development has played a crucial role in advancing therapeutic options for various diseases.

Collaborations

Schio has collaborated with notable colleagues in the industry, including Bruno Filoche-Romme and Frank Halley. Together, they have combined their expertise to foster innovation and drive the development of potentially life-saving treatments.

Conclusion

Laurent Schio's innovative spirit and scientific contributions have established him as a prominent figure in the pharmaceutical sector. With his extensive portfolio of patents and collaborations with esteemed professionals, he continues to influence the landscape of medical science and therapy development.

Profile summary based on public USPTO records.